Hormone Refractory Prostate Cancer (HRPC), also known as Castration-Resistant Prostate Cancer (CRPC), is a form of prostate cancer that no longer responds to hormone therapy. Most prostate cancers rely on male hormones known as androgens, such as testosterone, to grow. Hormone therapy, or androgen deprivation therapy (ADT), aims to reduce these hormone levels or block their effects. However, over time, the cancer may progress despite these treatments.
